Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373

被引：15

作者：

Alves, Katia ^{[1
]}

Plested, Joyce S. ^{[1
]}

Galbiati, Shirley ^{[1
]}

Chau, Gordon ^{[1
]}

Cloney-Clark, Shane ^{[1
]}

Zhu, Mingzhu ^{[1
]}

Kalkeri, Raj ^{[1
]}

Patel, Nita ^{[1
]}

Smith, Kathy ^{[1
]}

Marcheschi, Alex ^{[1
]}

Pfeiffer, Susan ^{[1
]}

McFall, Heather ^{[1
]}

Smith, Gale ^{[1
]}

Glenn, Gregory M. ^{[1
]}

Dubovsky, Filip ^{[1
]}

Mallory, Raburn M. ^{[1
]}

机构：

[1] Novavax, Gaithersburg, MD 20878 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2023年 / 388卷 / 09期

关键词：

D O I：

10.1056/NEJMc2215509

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Fourth Dose of SARS-CoV-2 Adjuvanted Protein VaccineBoosters of adjuvanted NVX-CoV2373 protein vaccine led to increasing neutralizing titers of antibody specific for the ancestral strain and omicron variants. Whether the elicited antibodies protect against infection is unclear.

引用

页码：857 / 859

页数：3

共 50 条

[41] NVX-Cov2373 Novavax Covid-19 vaccine: A further analysis of its efficacy using multiple modes of expression
Montastruc, Jean-Louis
Biron, Pierre
Sommet, Agnes
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 (06) : 1125 - 1127
[42] SARS-CoV-2 rS (NVX-CoV-2373) vaccine
不详
AUSTRALIAN PRESCRIBER, 2022, 45 (02) : 62 - 62
[43] Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
Gorman, Matthew J.
Patel, Nita
Guebre-Xabier, Mimi
Zhu, Alex L.
Atyeo, Caroline
Pullen, Krista M.
Loos, Carolin
Goez-Gazi, Yenny
Carrion, Ricardo, Jr.
Tian, Jing-Hui
Yuan, Dansu
Bowman, Kathryn A.
Zhou, Bin
Maciejewski, Sonia
McGrath, Marisa E.
Logue, James
Frieman, Matthew B.
Montefiori, David
Mann, Colin
Schendel, Sharon
Amanat, Fatima
Krammer, Florian
Saphire, Erica Ollmann
Lauffenburger, Douglas A.
Greene, Ann M.
Portnoff, Alyse D.
Massare, Michael J.
Ellingsworth, Larry
Glenn, Gregory
Smith, Gale
Alter, Galit
CELL REPORTS MEDICINE, 2021, 2 (09)
[44] Durability of Protection Against Coronavirus Disease 2019 (COVID-19) Through the Delta Surge for the NVX-CoV2373 Vaccine
Follmann, Dean
Mateja, Allyson
Fay, Michael P.
Magaret, Craig A.
Huang, Yunda
Fong, Youyi
Angier, Heather
Nason, Martha
Gay, Cynthia L.
Kotloff, Karen
Woo, Wayne
Cho, Iksung
Dunkle, Lisa M.
CLINICAL INFECTIOUS DISEASES, 2024, 79 (01) : 78 - 85
[45] Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase
Diego Macías Saint-Gerons
María Teresa Ibarz
José Luis Castro
Jaume Forés-Martos
Rafael Tabarés-Seisdedos
Drugs - Real World Outcomes, 2023, 10 : 263 - 270
[46] Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase
Macias Saint-Gerons, Diego
Ibarz, Maria Teresa
Castro, Jose Luis
Fores-Martos, Jaume
Tabares-Seisdedos, Rafael
DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 263 - 270
[47] Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
Heath, Paul T.
Galiza, Eva P.
Baxter, David Neil
Boffito, Marta
Browne, Duncan
Burns, Fiona
Chadwick, David R.
Clark, Rebecca
Cosgrove, Catherine A.
Galloway, James
Goodman, Anna L.
Heer, Amardeep
Higham, Andrew
Iyengar, Shalini
Jeanes, Christopher
Kalra, Philip A.
Kyriakidou, Christina
Bradley, Judy M.
Munthali, Chigomezgo
Minassian, Angela M.
McGill, Fiona
Moore, Patrick
Munsoor, Imrozia
Nicholls, Helen
Osanlou, Orod
Packham, Jonathan
Pretswell, Carol H.
Ramos, Alberto San Francisco
Saralaya, Dinesh
Sheridan, Ray P.
Smith, Richard
Soiza, Roy L.
Swift, Pauline A.
Thomson, Emma C.
Turner, Jeremy
Viljoen, Marianne Elizabeth
Fries, Louis
Cho, Iksung
McKnight, Irene
Glenn, Greg
Rivers, E. Joy
Robertson, Andreana
Alves, Katia
Smith, Kathy
Toback, Seth
CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : 398 - 407
[48] NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses
Moderbacher, Carolyn Rydyznski
Kim, Christina
Mateus, Jose
Plested, Joyce
Zhu, Mingzhu
Cloney-Clark, Shane
Weiskopf, Daniela
Sette, Alessandro
Fries, Louis
Glenn, Gregory
Crotty, Shane
JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (19):
[49] NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial
Marchese, Anthony M.
Zhou, Xiang
Kinol, John
Underwood, Eddie
Woo, Wayne
McGarry, Alice
Beyhaghi, Hadi
Anez, German
Toback, Seth
Dunkle, Lisa M.
VACCINE, 2023, 41 (22) : 3461 - 3466
[50] Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M™ adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial
Shinde, Vivek
Lombard Koen, Anthonet
Hoosain, Zaheer
Archary, Moherndran
Bhorat, Qasim
Fairlie, Lee
Lalloo, Umesh
Masilela, Mduduzi S. L.
Moodley, Dhayendre
Hanley, Sherika
Fouche, Leon Frederik
Louw, Cheryl
Tameris, Michele
Singh, Nishanta
Goga, Ameena
Dheda, Keertan
Grobbelaar, Coert
Joseph, Natasha
Lombaard, Johan J.
Mngqibisa, Rosie
Bhorat, As'ad Ebrahim
Benade, Gabriella
Lalloo, Natasha
Pitsi, Anna
Vollgraaff, Pieter-Louis
Luabeya, Angelique
Esmail, Aliasgar
Petrick, Friedrich G.
Oommen Jose, Aylin
Foulkes, Sharne
Ahmed, Khatija
Thombrayil, Asha
Kalonji, Dishiki
Cloney-Clark, Shane
Zhu, Mingzhu
Bennett, Chijioke
Albert, Gary
Marcheschi, Alex
Plested, Joyce S.
Neal, Susan
Chau, Gordon
Cho, Iksung
Fries, Louis
Glenn, Greg M.
Madhi, Shabir A.
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)

← 1 2 3 4 5 →